Kuhnil Pharmaceutical

Kuhnil Pharmaceutical is a South Korean pharmaceutical company focused on the development, manufacturing, and distribution of medicinal products. It has a diverse portfolio targeting cardiovascular diseases, central nervous system disorders—including pediatric insomnia—musculoskeletal disorders, gastrointestinal conditions, infectious diseases and oncology. The company has launched several innovative combination drugs such as ROSUMEGA® (rosuvastatin + omega‑3-acid ethyl esters) for dyslipidemia. Recent clinical results highlight the launch of Slenyto SR Tablet for pediatric insomnia in Korea; phase III trials showed significant improvements in sleep duration and latency among children/adolescents with ASD or SMS who did not respond to sleep hygiene interventions. The company also develops improved formulations using proprietary drug delivery technologies.